3-Methylbut-2-enoic acid

We are 3-Methylbut-2-enoic acid CAS:541-47-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-Methylbut-2-enoic acid
CAS.NO:541-47-9
Synonyms:3-Methylbut-2-enoic acid
β-Methylcrotonic acid
3,3-Dimethylacrylic acid
 
Physical and Chemical Properties:
Density 1.0±0.1 g/cm3
Boiling Point 194.5±0.0 °C at 760 mmHg
Melting Point 65-70 °C(lit.)
Molecular Formula C5H8O2
Molecular Weight 100.116
Flash Point 95.9±9.6 °C
Vapour Pressure 0.2±0.7 mmHg at 25°C
Index of Refraction 1.451
 
Specification:
Appearance:White acerate crystal
Assay:≥99.0%
Melting Point:65-70°C
Moisture:≤0.5%
Chromaticity:≤10
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Ciclopirox(CAS:29342-05-0).

3-Methylbut-2-enoic acid


Related News: At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.N-carbobenciloxi-L-valina CAS:1149-26-4 The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development.(R)-Propionyl Carnitine Chloride CAS:119793-66-7 The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development.D-glutamina CAS:5959-95-5 ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.

Related Products
Product Name
N-(tert-Butoxycarbonyl)-4-piperidone View Details
N-Phenylglycine View Details
(R)-tert-Butyl 3-hydroxypiperidine-1-carboxylate View Details
(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride manufacturer 2,6-Dichloronicotinic acid manufacturer 5-Fluoro-2-hydroxypyridine manufacturer N,N-dimethylformamide manufacturer 3-boc-amino-2,6-dioxopiperidine manufacturer